한국형 우울장애 약물치료 알고리듬 2021 (III) : 소아·청소년 = Korean Medication Algorithm Project for Depressive Disorder 2021 (III): Child and Adolescent

다국어 초록 (Multilingual Abstract)

Objectives The Korean Medication Algorithm Project for Depressive Disorder 2021 (KMAP-DD 2021) was a revision of previous works. The main purpose of the current study was to amend guidelines for the treatment of a major depressive disorder (MDD) for children and adolescents. Methods The survey consisted of 21 questionnaires for children and adolescents. A total of 33 of the 46 experts in child and adolescent psychiatry answered the survey. Results Antidepressant (AD) monotherapy was selected as the 1st line option for MDD with mild to moderate severity. As the 1st line of treatment for MDD severe without psychotic features in children and adolescents, AD monotherapy and AD augmented with atypical antipsychotics (AAP) were recommended. For MDD with psychotic features, AD augmented with AAP was preferred as the 1st line of treatment. Conclusion We developed an algorithm for child and adolescent populations with depressive disorders, more specifically than the KMAP-DD 2017. We expect this algorithm will provide clinicians useful information and help in the treatment of children and adolescents with depressive disorders.

목차 (Table of Contents)

• 서 론 방 법 결 과 고 찰 결 론

참고문헌 (Reference)

1 심세훈, "한국형 우울장애 약물치료 알고리듬 2017(V) : 소아·청소년/노인/여성" 대한우울조울병학회 15 (15): 91-102, 2017

2 서정석, "한국형 우울장애 약물치료 알고리듬 2006 (Ⅰ)" 대한신경정신의학회 46 (46): 453-460, 2007

3 조수철, "한국어판 DISC-IV(Diagnostic Interview Schedule for Children Version IV)의 신뢰도 및 타당도" 대한소아청소년 정신의학회 18 (18): 138-144, 2007

4 Emslie GJ, "Treatment of Resistant Depression in Adolescents(TORDIA) : week 24 outcomes" 167 : 782-791, 2010

5 Sachs GS, "The expert consensus guideline series : medication treatment of bipolar disorder 2000" 1-104, 2000

6 Grunze H, "The World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for the biological treatment of bipolar disorders : acute and long-term treatment of mixed states in bipolar disorder" 19 : 2-58, 2018

7 Seo SJ, "The Korean Medication Algorithm for Depressive Disorder : second revision" 167 : 312-321, 2014

8 Fountoulakis KN, "The International College of Neuro-Psychopharmacology (CINP)treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines" 20 : 180-195, 2017

9 Hughes CW, "Texas Children’s Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder" 46 : 667-686, 2007

10 Solmi M, "Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic metareview of 78 adverse effects" 19 : 214-232, 2020

11 Meador K, "Pregnancy outcomes in women with epilepsy: a systematic review and metaanalysis of published pregnancy registries and cohorts" 81 : 1-13, 2008

12 Birmaher B, "Practice parameter for the assessment and treatment of children and adolescents with depressive disorders" 46 : 1503-1526, 2007

13 Yoo HK, "Openlabel study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders" 20 : 127-135, 2011

14 Hetrick SE, "Newer generation antidepressants for depressive disorders in children and adolescents" (11) : 2012

15 Jeong Seok Seo, "Korean Medication Algorithm for Depressive Disorders 2017: Third Revision" 대한정신약물학회 16 (16): 67-87, 2018

16 Cipriani A, "Escitalopram versus other antidepressive agents for depression" (2) : 2009

17 Findling RL, "Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial" 23 : 468-480, 2013

18 Weisz JR, "Effects of psychotherapy for depression in children and adolescents : a meta-analysis" 132 : 132-149, 2006

19 Kukju Kweon, "Effectiveness and Safety of Bupropion in Children and Adolescents with Depressive Disorders: A Retrospective Chart Review" 대한정신약물학회 17 (17): 537-541, 2019

20 Tomson T, "Dose-dependent risk of malformations with antiepileptic drugs : an analysis of data from the EURAP epilepsy and pregnancy registry" 10 : 609-617, 2011

21 Baweja R, "Disruptive mood dysregulation disorder : current insights" 12 : 2115-2124, 2016

22 American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" American Psychiatric Publishing 2013

23 남범우, "Comparing the Effects of Bupropion and Escitalopram on Excessive Internet Game Play in Patients with Major Depressive Disorder" 대한정신약물학회 15 (15): 361-368, 2017

24 Song J, "Comparative study of the effects of bupropion and escitalopram on internet gaming disorder" 70 : 527-535, 2016

25 Cipriani A, "Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis" 388 : 881-890, 2016

26 Zhou X, "Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis" 7 : 581-601, 2020

27 Angold A, "Comorbidity" 40 : 57-87, 1999

28 Klein JB, "Cognitive-behavioral therapy for adolescent depression : a meta-analytic investigation of changes in effect-size estimates" 46 : 1403-1413, 2007

29 Birmaher B, "Childhood and adolescent depression: a review of the past 10 years. Part I" 35 : 1427-1439, 1996

30 MacQueen GM, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations:youth, women, and the elderly" 61 : 588-603, 2016

31 Giedd JN, "Brain development during childhood and adolescence : a longitudinal MRI study" 2 : 861-863, 1999

32 Center for Behavioral Health Statistics and Quality, "Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health" Substance Abuse and Mental Health Services Administration 2015

33 Patkar AA, "Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder" 27 (27): S29-S37, 2013

34 Nelson JC, "Atypical antipsychotic augmentation in major depressive disorder : a meta-analysis of placebo-controlled randomized trials" 166 : 980-991, 2009

35 Zhou X, "Atypical antipsychotic augmentation for treatment-resistant depression : a systematic review and network meta-analysis" 18 : 2015

36 Seida JC, "Antipsychotics for children and young adults : a comparative effectiveness review" 129 : e771-e784, 2012

37 Blader JC, "Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy" 166 : 1392-1401, 2009

38 Kalverdijk LJ, "A multi-national comparison of antipsychotic drug use in children and adolescents, 2005-2012" 11 : 55-, 2017

39 Lee ES, "A focused review on the treatment of pediatric patients with atypical antipsychotics" 28 : 582-605, 2018

40 Wagner KD, "A doubleblind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression" 45 : 280-288, 2006